Donahue Sarah, Ryan Joanne C, Podsada Kimberly
From UCSF Health, San Francisco, California.
Pfizer Inc., New York, NY.
J Adv Pract Oncol. 2024 Jul 22:1-14. doi: 10.6004/jadpro.2024.15.8.9.
Advanced practice providers in oncology are now likely to encounter real-world data (RWD) studies in addition to data from randomized controlled trials (RCTs) in their practice. Real-world evidence derived from RWD can provide important information about a therapeutic agent's effectiveness outside of the confines of RCTs. It is important to understand how these studies are conducted and how data from these two types of studies can be interpreted and integrated for practical clinical use and shared decision-making. The goal of this manuscript is to provide an overview of the fundamental aspects of RWD studies and what is required to conduct a robust RWD study. Recently published studies are cited to demonstrate how RWD studies complement RCTs.
肿瘤学领域的高级执业人员如今在其临床实践中,除了会遇到来自随机对照试验(RCT)的数据外,还很可能会接触到真实世界数据(RWD)研究。从RWD得出的真实世界证据能够提供有关治疗药物在RCT范围之外有效性的重要信息。了解这些研究是如何开展的,以及如何解读和整合这两类研究的数据以用于实际临床应用和共同决策,这很重要。本文的目的是概述RWD研究的基本方面以及开展一项有力的RWD研究所需的条件。引用最近发表的研究来说明RWD研究如何补充RCT。